Міжн. реєстрація № 1883758 fbПоширити

(540)
Зображення знака
ZOBILTY
(151)
Дата реєстрації
08.08.2025
(180)
Очікувана дата закінчення строку дії реєстрації/продовження
08.08.2035
(270)
Мова заявки
Англійська
(732)
Ім'я та адреса власника реєстрації

Avidity Biosciences, Inc.
3020 Callan Road
San Diego, California 92121 (US)

(740)
Ім'я та адреса представника

Aaron D. Hendelman
WILSON SONSINI GOODRICH & ROSATI
650 Page Mill Road
Palo Alto CA 94304 (US)

(770)
Ім'я та адреса попереднього заявника або власника

Avidity Biosciences, Inc.
10578 Science Drive, Suite 125
San Diego CA 92121 (US)

(511)
Індекси Міжнародної класифікації товарів і послуг (Ніццької класифікації) та перелік товарів і послуг
Кл.05

Англ.Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of and prevention of musculoskeletal, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, and muscle atrophy related diseases and disorders; pharmaceutical preparations for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; therapeutic pharmaceutical for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; therapeutic pharmaceuticals for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes.

Кл.40

Англ.Custom manufacturing of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies; custom manufacturing of pharmaceuticals; contract manufacturing in the field of pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing.

Кл.42

Англ.Medical and scientific research, namely, conducting clinical trials for others; providing medical and scientific research information in the fields of pharmaceuticals, biotechnology, and clinical trials; pharmaceutical research and development; pharmaceutical products development; research and development in the field of biotechnology.

Кл.44

Англ.Providing information in the fields of pharmaceuticals, therapeutics, healthcare, medicines, vaccines, health conditions, health awareness and treatment options; medical information services, namely, providing information related to healthcare, diseases, disorders, and treatment options; providing information related to healthcare, health awareness, medicines, vaccines, diseases, disorders, and treatment options via a website.

(821)
Базова заявка
US, 12.02.2025, 99038933
(300)
Дані щодо пріоритету відповідно до Паризької конвенції
US, 12.02.2025, 99038933
(832)
Зазначено відповідно до Мадридського Протоколу
AE · AU · BA · BY · CL · EG · IL · IS · KR · LI · ME · MX · OM · QA · RS · SG · UA
(527)
Зазначення щодо вимог, які стосуються використання
SG